Navigation Links
SKorean Scientists Develop Technology for Cheap Biosensor

South Korean scientists said Monday they had developed new technology to use transistors in devices for quick diagnosis of diseases such as diabetes.

The biosensor technology was developed by a research team at the state-run Korea Advanced Institute of Science and Technology.

"We proved that transistors can be used not only for computers but also for devices that convert biological responses into electrical signals," team leader Choi Yang-Kyu told AFP.

Biosensors detect biological responses or changes and convert them into an electrical signal that can be read. Currently, they are electrochemical or optical.

"But our technology using existing transistors will open the way for the mass production of cheap but highly efficient biosensors," he said.

"We have developed technology to create a tiny gap on a transistor to fill it with bio-molecules, or biologically responsive materials that detect diseases," he said.

He said the new technology could be applied to healthcare, food quality appraisal or environmental monitoring.

"I believe a cell phone equipped with a cheap biosensor can be produced in the near future," he said.

One of the most widespread uses of biosensors is by people with diabetes who need to regularly monitor their blood-glucose levels.


'"/>




Page: 1

Related medicine news :

1. SKorean University Seeks to Bar Smokers
2. Scientists plan human cloning clinic in the United States
3. Scientists found ancient Human Germ Killer
4. Scientists locate key hormone involved in appetite control
5. Scientists open the book of life
6. Scientists review SARS
7. Scientists crack dengue fever puzzle
8. Scientists push to lower hidden sodium in food
9. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
10. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
11. Scientists reveal the secrets of sarcasm
Post Your Comments:
(Date:5/16/2008)... that Primary care medicine is in a precipitous de...merican College of Physicians (ACP), today joined...sumers to issue a call for comprehensive reforms t...nd other primary care physicians. , During a pa...ne in the U.S., Dr. Dale and other panelists spoke...
(Date:5/16/2008)...ervices for Frail Seniors and People With,Disabili...ire/ -- Thousands of,homecare workers across the s...proposed cuts to hours of service, wages and benef...ulnerable workers and the,people they serve deeper...rvices for seniors and people with disabilities fr...
(Date:5/16/2008)...alth Institute with 10,000 Sensual O Condom Packs ...Mansion Fundraiser, LOS ANGELES, May 16 /PRNewswi... B artist J Kwon known best for his hit song "Ever...ng the Urban Health Institute (UHI) with,10,000 Se... The donation is,being made to promote the launch ...
(Date:5/16/2008)... who would benefit most from chemo after surgery, ... News) -- A panel of 15 genes may help determine w... cancer will experience a recurrence and, therefor... shows. , By extension, the same genetic signa...ve forms of the cancer who would be able to forego...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...t deadly form of skin cancer , advanced melanoma c...ts with tumor proteins, say researchers according ...ect vaccinating patients with tumor antigens (call...e cells, which are known as killer T-cells. It was...
...iscovery could help prevent complications for preg...lampsia. Preeclampsia typically develops after the...gh blood pressure, // edema, and protein in the u...here a sharp rise in blood pressure causes the mot...
... killer cells are part of the body’s immune system...ome cancers, particularly leukemia. A new study sh...emia // patients may lie in artificially stimulat...member. Researchers say this method could help tr...
...hers say they have found that stem cell therapy is...uring the study injecting stem cells from one pig'...ig's damaged heart muscle restored the heart's fun...hers studied 14 pigs, whose circulatory systems ar...
Other Medicine News:
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating th...linically meaningful extension of progression-free...mab to attack both the inside and,outside of the H...ade, -- Data demonstrating activity of TYKERB alo...ple lines of trastuzumab and chemotherapy, LONDON...
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 1PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 2CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 1CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 2TOFUTTI Announces 2007 Results 16776 1TOFUTTI Announces 2007 Results 16776 2TOFUTTI Announces 2007 Results 16776 3TOFUTTI Announces 2007 Results 16776 4TOFUTTI Announces 2007 Results 16776 5Testosterone Spray Improves Sexual Satisfaction in Women 16771 1Testosterone Spray Improves Sexual Satisfaction in Women 16771 2
... June 4, 2007 – Data presented,today at this...y,(ASCO) meeting in Chicago show that a novel comb...-fluorouracil (5-FU) therapy UFT,(tegafur–ur...response rate in the first-line treatment of metas...dy (Study of CPT-11 with Oxaliplatin combined,with...
...ing a clinically relevant model of,normal human sk...,of abrogating the cytotoxic effect of erlotinib *...m) agent was generally well,tolerated in metastati...similar to conventional vincristine , SOUTH SAN FR...Hana Biosciences (Nasdaq:HNAB), a biopharmaceutica...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Medicine Products: